M Olivieri1, J Heinrich2,3, V Schlünssen4, J M Antó5,6,7,8, B Forsberg9, C Janson10, B Leynaert11,12, D Norback13, T Sigsgaard4, C Svanes14,15, C Tischer2,5,7,8, S Villani16, D Jarvis17,18, G Verlato19. 1. Unit of Occupational Medicine, University Hospital of Verona, Verona, Italy. 2. Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany. 3. Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital Munich, Ludwig Maximilians University Munich, Munich, Germany. 4. Department of Public Health, Section of Environment, Occupation and Health, Danish Ramazzini Centre, Aarhus University, Aarhus, Denmark. 5. Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. 6. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 7. Universitat Pompeu Fabra (UPF), Barcelona, Spain. 8. CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 9. Department of Public Health and Clinical Medicine, Division of Occupational and Environmental Medicine, Umea University, Umea, Sweden. 10. Department of Medical Sciences/Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden. 11. Inserm, UMR 1152, Pathophysiology and Epidemiology of Respiratory Diseases, Paris, France. 12. University Paris Diderot Paris 7, UMR 1152, Paris, France. 13. Department of Medical Science/Occupational and Environmental Medicine, Uppsala University, Uppsala, Sweden. 14. Centre for International Health, University of Bergen, Bergen, Norway. 15. Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway. 16. Unit of Biostatistics and Clinical Epidemiology, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. 17. Respiratory Epidemiology and Public Health Group, Imperial College London, London, United Kingdom. 18. MRC-PHE Centre for Environment and Health, Imperial College, London, United Kingdom. 19. Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Abstract
BACKGROUND: The relation between IgE sensitization and allergic respiratory symptoms has usually been evaluated by dichotomizing specific IgE levels. The aim of this study was to evaluate the association between specific IgE levels and risk of symptoms on allergen-related exposure, with special reference to allergen-related asthma-rhinitis comorbidity. METHODS: We considered 6391 subjects enrolled within the European Community Respiratory Health Survey 2, having information on cat/grass/D. pteronyssinus IgE levels and symptoms on exposure to animals/pollen/dust. The risk of oculonasal/asthmalike/both symptoms was evaluated by a multinomial logistic model. RESULTS: A clear positive association was observed between specific IgE levels to cat/grass/mite and the risk of symptoms on each allergen-related exposure (test for trend with P < 0.001). This trend was particularly pronounced when considering the coexistence of asthmalike and oculonasal symptoms. Compared to non-sensitized subjects, subjects with specific IgE to cat >= 3.5 kU/l presented relative risk ratios of 11.4 (95% CI 6.7-19.2), 18.8 (8.2-42.8), and 55.3 (30.5-100.2) when considering, respectively, only oculonasal symptoms, only asthmalike symptoms, or both. A similar pattern was observed when considering specific IgE to grass/mite and symptoms on exposure to pollen/dust. Also the proportion of people using inhaled medicines or visiting a general practitioner for breathing problems in the previous year increased with increasing sum of specific IgE to cat/grass/mite. CONCLUSION: Specific IgE level is the most important predictor of allergen-related symptoms. The risk of both oculonasal/asthmalike symptoms increases with specific IgE levels, suggesting that specific IgE contributes to the 'united airways disease'.
BACKGROUND: The relation between IgE sensitization and allergic respiratory symptoms has usually been evaluated by dichotomizing specific IgE levels. The aim of this study was to evaluate the association between specific IgE levels and risk of symptoms on allergen-related exposure, with special reference to allergen-related asthma-rhinitis comorbidity. METHODS: We considered 6391 subjects enrolled within the European Community Respiratory Health Survey 2, having information on cat/grass/D. pteronyssinus IgE levels and symptoms on exposure to animals/pollen/dust. The risk of oculonasal/asthmalike/both symptoms was evaluated by a multinomial logistic model. RESULTS: A clear positive association was observed between specific IgE levels to cat/grass/mite and the risk of symptoms on each allergen-related exposure (test for trend with P < 0.001). This trend was particularly pronounced when considering the coexistence of asthmalike and oculonasal symptoms. Compared to non-sensitized subjects, subjects with specific IgE to cat >= 3.5 kU/l presented relative risk ratios of 11.4 (95% CI 6.7-19.2), 18.8 (8.2-42.8), and 55.3 (30.5-100.2) when considering, respectively, only oculonasal symptoms, only asthmalike symptoms, or both. A similar pattern was observed when considering specific IgE to grass/mite and symptoms on exposure to pollen/dust. Also the proportion of people using inhaled medicines or visiting a general practitioner for breathing problems in the previous year increased with increasing sum of specific IgE to cat/grass/mite. CONCLUSION: Specific IgE level is the most important predictor of allergen-related symptoms. The risk of both oculonasal/asthmalike symptoms increases with specific IgE levels, suggesting that specific IgE contributes to the 'united airways disease'.
Authors: Ji Ho Lee; Su Chin Kim; Hyunna Choi; Chang Gyu Jung; Ga Young Ban; Yoo Seob Shin; Dong Ho Nahm; Hae Sim Park; Young Min Ye Journal: Allergy Asthma Immunol Res Date: 2018-01 Impact factor: 5.764
Authors: Therese Sterner; Ada Uldahl; Åke Svensson; Magnus P Borres; Sigrid Sjölander; Alf Tunsäter; Jonas Björk; Cecilia Svedman; Magnus Bruze; Laura von Kobyletzki; Hampus Kiotseridis Journal: Clin Mol Allergy Date: 2019-04-02